Novo Nordisk parent buys US drug firm for $16.5bn to expand Wegovy supply
The explosion in demand for the weight-loss drug Wegovy has led to the holding company behind its maker, Novo Nordisk, buying a leading US-based drugmaker for $16.5bn (£13.2bn) to increase capacity. Novo Holdings is to buy the New Jersey-based pharmaceutical firm Catalent, and then immediately…
#novonordisk #novoholdings #newjersey #catalent #wegovynovonordisk #wegovyandozempic #novonordisks #danish #novo #elonmusk
